Evolus, Inc. (NASDAQ:EOLS) Shares Acquired by Bank of America Corp DE

Bank of America Corp DE boosted its stake in Evolus, Inc. (NASDAQ:EOLS) by 6.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 158,671 shares of the company’s stock after buying an additional 9,440 shares during the period. Bank of America Corp DE owned 0.25% of Evolus worth $1,752,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Ameriprise Financial Inc. raised its holdings in Evolus by 11.4% during the fourth quarter. Ameriprise Financial Inc. now owns 80,446 shares of the company’s stock worth $888,000 after purchasing an additional 8,214 shares in the last quarter. Allostery Investments LP bought a new stake in shares of Evolus in the 4th quarter worth $4,760,000. Caligan Partners LP raised its stake in shares of Evolus by 22.7% in the 4th quarter. Caligan Partners LP now owns 2,692,388 shares of the company’s stock worth $29,724,000 after buying an additional 498,900 shares in the last quarter. Freestone Grove Partners LP acquired a new stake in shares of Evolus in the fourth quarter valued at $140,000. Finally, Comerica Bank bought a new position in Evolus during the fourth quarter valued at about $312,000. 90.69% of the stock is currently owned by institutional investors.

Evolus Stock Performance

Shares of EOLS stock opened at $9.96 on Wednesday. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. Evolus, Inc. has a 52 week low of $8.67 and a 52 week high of $17.82. The company’s 50 day moving average price is $10.52 and its two-hundred day moving average price is $11.94. The company has a market capitalization of $642.18 million, a P/E ratio of -10.94 and a beta of 1.11.

Insider Buying and Selling at Evolus

In other Evolus news, insider Rui Avelar sold 27,904 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total transaction of $370,007.04. Following the completion of the sale, the insider now directly owns 362,467 shares of the company’s stock, valued at approximately $4,806,312.42. The trade was a 7.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Karah Herdman Parschauer sold 12,888 shares of Evolus stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $12.99, for a total transaction of $167,415.12. Following the transaction, the director now directly owns 32,183 shares in the company, valued at approximately $418,057.17. This represents a 28.59% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 86,241 shares of company stock valued at $1,048,666. 5.90% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on EOLS shares. Needham & Company LLC reissued a “buy” rating and set a $22.00 price objective on shares of Evolus in a research note on Thursday, May 8th. Barclays upped their target price on Evolus from $22.00 to $25.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. BTIG Research initiated coverage on Evolus in a research note on Thursday, April 17th. They issued a “buy” rating and a $21.00 price target on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $27.00 price objective on shares of Evolus in a research note on Thursday, April 10th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $23.75.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.